Table 2 Clinical characteristics of all patients
From: Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients
| Â | Hodgkin lymphoma N (%) | High-grade B-cell lymphoma N (%) | All lymphoma patients N (%) | Healthy blood donors N (%) |
|---|---|---|---|---|
Patients | 19 | 24 | 43 | 15 |
Male | 13 (68) | 16 (67) | 29 (67) | 9 (75) |
Female | 6 (32) | 8 (33) | 14 (33) | 3 (25) |
Unknown | Â | Â | Â | 3 |
Age | ||||
 Mean (range) | 47 (22–84) | 64 (35–85) | 57 (22–85) | 44 (20–69) |
 Relapse | 1 (5) | 1 (4) |  |  |
 RT only |  | 2 (8) |  |  |
 R-CHOP |  | 20 (83) |  |  |
 ABV/ABVD | 14 (74) |  |  |  |
 BEACOPP | 2 (10) |  |  |  |
 Other treatment | 3 (16) | 2(8) |  |  |
 PD | 3 (16) | 2 (8) |  |  |
 DWD | 3 (16) | 3 (12) | 6 (14) |  |
 AWD | 1 (5) | 0 (0) |  |  |
 Median follow-up time | 23 | 18 | 19.8 |  |
 Mean follow-up time (range) | 20 (1–40) | 23 (3–52) | 21 (1–52) |  |
 ADF | 15 (79) | 19 (79) |  |  |
Stage | ||||
 1A | 2 (10.5) | 9 (38) |  |  |
 1B | 2 (10.5) | – |  |  |
 2A | 4 (21) | 2 (8) |  |  |
 2B | 2 (10.5) | 2 (8) |  |  |
 3A | 3 (16) | 5 (21) |  |  |
 3B | 3 (16) | 1 (4) |  |  |
 4A | 2 (10.5) | 1 (4) |  |  |
 4B | 1 (5) | 4 (17) |  |  |
 B-symptoms | 8 (42) | 8 (33) | 16 (37) |  |
IPS | ||||
 0–1 | 4 (21) | – |  |  |
 2 | 7 (37) | – |  |  |
 3 | 7 (37) | – |  |  |
  > 4 | 1 (5) | – |  |  |
IPI | ||||
 0–1 | – | 12 (50) |  |  |
 2 | – | 5 (21) |  |  |
 3 | – | 4 (17) |  |  |
 4 | – | 3 (12) |  |  |